APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Glucagon Like Peptide-1 (GLP-1) Agonists

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Selected research

Market Analysis & Forecast

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032

Report ID 173995480226 December 2025192 pages

Choose your research edition.

Industry ResearchGlucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Read the full market overview

This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Company

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

Hospital

Pharmacy

Other

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exenatied Major Manufacturers Table 3. Liraglutide Major Manufacturers Table 4. Lixisenatide Major Manufacturers Table 5. Albiglutide Major Manufacturers Table 6. Dulaglutide Major Manufacturers Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Manufacturers Table 9. Pharmacy Major Manufacturers Table 10. Other Major Manufacturers Table 11. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends Table 12. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers Table 13. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges Table 14. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2026) Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2027-2032) Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (K Units) Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032) & (K Units) Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2026) Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2027-2032) Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2021-2026) Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers, Product Type & Application Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2026) Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2027-2032) Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2026) Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2027-2032) Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2026) & (USD/Unit) Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2027-2032) & (USD/Unit) Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2026) Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2027-2032) Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2026) Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2027-2032) Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2026) & (USD/Unit) Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2027-2032) & (USD/Unit) Table 60. Novo Nordisk Company Information Table 61. Novo Nordisk Business Overview Table 62. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 63. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 64. Novo Nordisk Recent Development Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 69. AstraZeneca Recent Development Table 70. Eli Lily Company Information Table 71. Eli Lily Business Overview Table 72. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 74. Eli Lily Recent Development Table 75. GSK Company Information Table 76. GSK Business Overview Table 77. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 79. GSK Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 84. Sanofi Recent Development Table 85. Bristol-Myers Squibb Company Information Table 86. Bristol-Myers Squibb Business Overview Table 87. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 89. Bristol-Myers Squibb Recent Development Table 90. Amylin Company Information Table 91. Amylin Business Overview Table 92. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 94. Amylin Recent Development Table 95. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 98. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 99. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2021-2026) & (USD/Unit) Table 100. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2027-2032) & (USD/Unit) Table 101. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 104. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 105. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2021-2026) & (USD/Unit) Table 106. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2027-2032) & (USD/Unit) Table 107. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 109. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 110. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 111. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 112. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 113. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2021-2026) & (USD/Unit) Table 114. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2027-2032) & (USD/Unit) Table 115. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 116. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 117. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 118. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 121. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 122. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2021-2026) & (USD/Unit) Table 123. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2027-2032) & (USD/Unit) Table 124. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 127. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 128. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2021-2026) & (USD/Unit) Table 129. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2027-2032) & (USD/Unit) Table 130. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 134. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 135. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 136. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2021-2026) & (USD/Unit) Table 137. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2027-2032) & (USD/Unit) Table 138. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 139. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 140. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 141. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 142. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 143. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 144. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 145. Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 146. Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 147. Poland Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 148. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 149. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 150. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 151. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 152. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2021-2026) & (USD/Unit) Table 153. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2027-2032) & (USD/Unit) Table 154. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 155. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 156. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 157. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 158. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2021-2026) & (USD/Unit) Table 159. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2027-2032) & (USD/Unit) Table 160. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 163. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 164. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2021-2026) & (USD/Unit) Table 165. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2027-2032) & (USD/Unit) Table 166. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 169. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 170. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2021-2026) & (USD/Unit) Table 171. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2027-2032) & (USD/Unit) Table 172. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 176. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 177. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 178. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2021-2026) & (USD/Unit) Table 179. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2027-2032) & (USD/Unit) Table 180. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 181. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 182. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 183. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 184. Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 185. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 186. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 187. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 188. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 189. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 190. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2021-2026) & (USD/Unit) Table 191. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Type (2027-2032) & (USD/Unit) Table 192. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 193. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 194. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 195. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 196. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2021-2026) & (USD/Unit) Table 197. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Application (2027-2032) & (USD/Unit) Table 198. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 202. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 203. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 204. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2021-2026) & (USD/Unit) Table 205. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Country (2027-2032) & (USD/Unit) Table 206. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 207. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 208. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 209. Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 210. Peru Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 211. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 212. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 213. UAE Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 214. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 215. Iran Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 216. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List Table 220. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Image Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exenatied Image Figure 5. Liraglutide Image Figure 6. Lixisenatide Image Figure 7. Albiglutide Image Figure 8. Dulaglutide Image Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Pharmacy Image Figure 13. Other Image Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2032) Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032) & (K Units) Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2021-2032) & (K Units) Figure 23. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2021-2032) & (K Units) Figure 24. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2021-2032) & (K Units) Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032) Figure 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032) Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032) Figure 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032) Figure 42. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2021-2032) Figure 43. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2021-2032) Figure 44. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2021-2032) Figure 45. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2021-2032) Figure 46. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2021-2032) Figure 47. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2021-2032) Figure 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2021-2032) Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2021-2032) Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2021-2032) Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2021-2032) Figure 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2021-2032) Figure 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2021-2032) Figure 54. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2021-2032) Figure 55. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2021-2032) Figure 56. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2021-2032) Figure 57. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2021-2032) Figure 58. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2021-2032) Figure 59. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2021-2032) Figure 60. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2021-2032) Figure 61. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2021-2032) Figure 62. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2021-2032) Figure 63. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2021-2032) Figure 64. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2021-2032) Figure 65. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2021-2032) Figure 66. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2021-2032) Figure 67. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2021-2032) Figure 68. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2021-2032) Figure 69. SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2021-2032) Figure 70. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatied
  • Liraglutide
  • Lixisenatide
  • Albiglutide
  • Dulaglutide
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb
  • Amylin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
  3. 1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exenatied
  5. 1.2.3 Liraglutide
  6. 1.2.4 Lixisenatide
  7. 1.2.5 Albiglutide
  8. 1.2.6 Dulaglutide
  9. 1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
  10. 1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Pharmacy
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
  1. 2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
  2. 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
  3. 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
  4. 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
  3. 3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021-2026)
  5. 3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2027-2032)
  6. 3.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
  9. 3.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026)
  11. 3.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032)
  12. 3.4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers
  2. 4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers
  6. 4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers, Product Type & Application
  13. 4.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
  16. 4.8.2 2025 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier 3
5 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
  1. 5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
  2. 5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
  6. 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032)
  9. 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type
6 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
  1. 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application
  2. 6.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
  6. 6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032)
  9. 6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application
7 Company Profiles
  1. 7.1 Novo Nordisk
  2. 7.1.1 Novo Nordisk Company Information
  3. 7.1.2 Novo Nordisk Business Overview
  4. 7.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  6. 7.1.5 Novo Nordisk Recent Developments
  7. 7.2 AstraZeneca
  8. 7.2.1 AstraZeneca Company Information
  9. 7.2.2 AstraZeneca Business Overview
  10. 7.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  12. 7.2.5 AstraZeneca Recent Developments
  13. 7.3 Eli Lily
  14. 7.3.1 Eli Lily Company Information
  15. 7.3.2 Eli Lily Business Overview
  16. 7.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  18. 7.3.5 Eli Lily Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Bristol-Myers Squibb
  32. 7.6.1 Bristol-Myers Squibb Company Information
  33. 7.6.2 Bristol-Myers Squibb Business Overview
  34. 7.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb Recent Developments
  37. 7.7 Amylin
  38. 7.7.1 Amylin Company Information
  39. 7.7.2 Amylin Business Overview
  40. 7.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  42. 7.7.5 Amylin Recent Developments
8 North America
  1. 8.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  2. 8.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  3. 8.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  4. 8.1.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
  5. 8.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 8.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  7. 8.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 8.2.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
  9. 8.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  10. 8.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  2. 9.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  3. 9.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  4. 9.1.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
  5. 9.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 9.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  7. 9.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 9.2.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
  9. 9.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  10. 9.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  2. 10.1.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  3. 10.1.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  4. 10.1.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
  5. 10.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 10.2.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  7. 10.2.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 10.2.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  2. 11.1.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  3. 11.1.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  4. 11.1.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
  5. 11.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 11.2.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  7. 11.2.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 11.2.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
  9. 11.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  10. 11.3.1 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Glucagon Like Peptide-1 (GLP-1) Agonists Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type
  2. 12.1.1 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
  5. 12.2 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application
  6. 12.2.1 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
  9. 12.3 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country
  10. 12.3.1 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Glucagon Like Peptide-1 (GLP-1) Agonists Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
  2. 13.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
  6. 13.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
  9. 13.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst